Deborah P. Beebe is seeking a senior project manager position to utilize her 30 years of experience in biomedical research and project management. She has a PhD in Immunology and is a certified Project Management Professional (PMP). Her experience includes 9 years as Senior Project Manager at the National Cancer Institute and 15 years of progressive leadership roles at the National Heart, Lung, and Blood Institute including scientific review administrator, branch chief, and division director. She also has experience managing budgets, conducting research, and overseeing FDA regulatory processes for drug and biologic approvals.

1. 1 0 1 1 7 T E N B R O O K D R I V E • S I L V E R S P R I N G , • M A R Y L A N D 2 0 9 0 1
P H O N E 2 4 0 - 3 9 3 - 5 6 1 4 • E - M A I L D E B O R A H . P . B E E B E @ G M A I L . C O M
D E B O R A H P . B E E B E , P H . D . , P M P
OBJECTIVE
As Senior Project Manager of CIAT, I seek to promote health
research with professional and managerial skills acquired over
30 years of involvement in the biomedical health profession.
SUMMARY OF QUALIFICATIONS
 Project Management: PMI certified Project Manager with 9 years
experience as Senior Project Manager of the Cancer Information
Tracking and Analysis Contract (CIAT) with the National Cancer
Institute (NCI, National Institutes of Health (NIH) at ICF International.
 NIH Leadership: 15 years experience at the National Heart, Lung,
and Blood Institute progressing from Scientific Review Administrator
(SRA), to SRA Group Leader, Chief of Scientific Review Branch, and
Director of the Division of Extramural Affairs.
 Strategic Planning and Career Counseling: experience with
strategic planning for the Division of Extramural Affairs at NHLBI to
define Vision, Mission, Strategic Goals, and Core Values, counseling and
mentoring employees.
 Professional Presentations: experience with presentations both
informational and visionary to a wide variety of audiences.
 Program Policy Oversight: experience with NIH program, grants
management and contract operation policies as well as specific NHLBI
program and financial policies for the Division of Extramural Affairs.
 Financial Oversight: experience with managing budgets for project,
NIH grants and contracts
 Research Integrity Oversight: experience as the Research Integrity
Officer for the NHLBI with responsibility for handling reports of
extramural scientific misconduct.
 Executive secretary of the NHLBI Advisory Council
 FDA Regulatory experience: experience with the FDA regulatory
process including INDs, PLAs and ELAs for biologic products.

2. EDUCATION
Degree: Bachelor of Arts, Magna cum Laude, Phi Beta Kappa
Major: Chemistry with Honors
University: Connecticut College, New London, Connecticut
Degree: Doctor of Philosophy
Major: Immunology
University: University of Connecticut Health Center, Farmington,
Connecticut.
PROFESSIONAL EXPERIENCE
 Staff Scientist, Division of Blood and Blood Products, Center for
Biologics Evaluation and Research, FDA, Bethesda, MD.
 Scientific Review Administrator, Review Branch, National Heart, Lung,
and Blood Institute, NIH, Bethesda, MD.
 Group Leader, Heart and Lung Review Group, Review Branch,
National Heart, Lung, and Blood Institute, NIH, Bethesda, MD.
 Chief, Review Branch, National Heart, Lung, and Blood Institute, NIH,
Bethesda, MD.
 Director, Division of Extramural Affairs, National Heart, Lung,
and Blood Institute, NIH, Bethesda, MD
 Senior Project Manager, ICF International, Cancer Information,
Analysis and Tracking (CIAT) contract with the National Cancer
Institute, NIH 2006-present.
PUBLICATIONS
1. Beebe, D.P., Ward, P.A., and Spitznagel, J.K., Isolation and characterization of
an acidic chemotactic factor from complement- activated human serum. Clin.
Immunol. Immunopath. 15:88-105, 1980.
2. Muhlfelder, T.W., Niemetz, J., Kreutzer, D., Beebe, D.P., Ward, P.A., and
Rosenfeld, S.T. C5 chemotactic fragment induces leukocyte production of tissue
factor activity: a link between complement and coagulation. J. Clin. Invest. 63:147,
1979.
3. Mills, B.J., Beebe, D.P., and Cooper, N.R. Antibody-dependent neutralization
of vesicular stomatitis virus by human complement. J. Immunol. 123:2518-2524,

3. 1979.
4. Beebe, D.P. and Cooper, N.R. Neutralization of vesicular stomatitis virus
(VSV) by human complement requires a natural IgM antibody present in human
serum. J. Immunol. 126:1562-1568, 1981.
5. Beebe, D.P., Schreiber, R., and Cooper, N.R. Neutralization of influenza virus
by normal human serum. J. Immunol. 130:1317-1322, 1983.
6. Cooper, N.R., Beebe, D.P., and Nemerow, G.R. Mechanisms of complement-
dependent viral neutralization. Immunopathology. VIIIth International
Symposium, Academic Press, pp. 529-557, 1982.
7. Faquet, G.B., and Beebe, D.P., Binding interaction studies of selected receptor
subpopulations after partial cross-linking of receptor-ligand complexes with a
photoactivated heterobifunctional reagent. J. Clin. Invest. 78:67-72, 1986.
8. Beebe, D.P., and Aronson, D.L. Turnover of human tissue plasminogen
activator (tPA) in rabbits. Thrombosis Research 43:663-674, 1986.
9. Beebe, D.P. Binding of tissue plasminogen activator (tPA) to human umbilical
vein endothelial cells (HUVEC). Thromb. Res. 46:241-254, 1987.
10. Beebe, D.P., and Faguet, G.B. Nutritional requirements of human malignant
(leukemic) cells: implications for adjuvant therapy. Cancer Research 47:2380-2384,
1987.
11. Beebe, D.P., and Aronson, D.L. An Automated assay for fibrinolytic agents
in microtiter plates. Thromb. Res. 47: 123-128, 1987.
12. Beebe, D.P., and Aronson, D.L. Turnover of tPA in Rabbits: influence of
carbohydrate moieties. Thromb. Res. 51:11-22, 1988.
13. Beebe, D.P., Miles, L.A., and Plow, E.F. A linear amino acid sequence
involved in the interaction of t-PA with its endothelial cell receptor. Blood
74:2034-2037, 1989.
14. Beebe, D.P., Wood, L.L., and Moos, M. Characterization of tissue
plasminogen activator binding proteins isolated from endothelial cells and other
cell types. Thromb. Res. 59:339-350, 1990.
15. Beebe, D.P., and Wood, L.L. A Collaborative Study to Establish a U.S.
Reference for Tissue Plasminogen Activator (t-PA). Biologicals 19: 229-232, 1991.
16. Henkin, J., Dudlak, D., Beebe, D.P., and Sennello, L. High Sialic Acid
Content Slows Prourokinase Turnover in Rabbits. Thromb. Res. 63: 215-225,
1991.
17. Beebe, D.P., Gaffney, P.J., and van Schie, D.M.V. Potency Assays for
Anistreplase: Comparison of the Fibrin Plate Assay and a 96-well Plate Assay.
Biologicals. 20:129-133, 1992.
18. Beebe, D. and Murano, G. Tissue Plasminogen Activator: Regulatory Issues.
in Regulatory Practice in Biotechnology ed. A.S. Lubiniecki and S. Vargo. 1994.

4. Doctoral Thesis: "Isolation and Characterization of a Chemotactic Factor from
Complement-Activated Human Serum", D.P. Beebe, University of Connecticut.
SCIENTIFIC ABSTRACTS AND PRESENTATIONS
1. Beebe, D., Goralnick, S., Gerard, C., Ozols, J., and Ward, P.A. The C5
chemotactic fragment isolated from activated human serum. J. Immunol. 120:
1764, 1987.
2. Beebe, D.P., Mills, B.J., and Cooper, N.R. Complement-dependent
neutralization of vesicular stomatitis virus (VSV). J. Immunol. 124: 1514, 1980.
3. Beebe, D.P., Schreiber, R., and Cooper, N.R. Neutralization of influenza virus
by normal human serum. FASEB, 1982.
4. Beebe, D.P. Binding of tissue plasminogen activator to human umbilical vein
endothelial cells. FASEB, 1987.
5. Beebe, D.P. and Aronson, D.L. Turnover of tissue plasminogen activator in
rabbits. FASEB, 1988.
6. Beebe, D.P. and Miles, L., and Plow, E. Tissue plasminogen activator binding
to endothelial cells: inhibition by a peptide from the finger region. Am. Heart
Assoc., 1988.
7. Beebe, D. and Wood, L. Characterization of a cellular binding protein
for tissue plasminogen activator. Am. Soc. of Hematology, 1989.
8. Beebe, D. Characterization of a t-PA Membrane Receptor. Gordon Conference
on Thrombolysis, Ventura, CA, March 30, 1990.
9. Beebe, D. Automated Fibrinolytic Assay: Experience with t-PA and APSAC.
American Association of Pharmaceutical Scientists. Eastern Regional Meeting,
June 4-5, 1990.
COLLABORATIONS
 1987- A Collaborative Study to Establish the Second International Standard for Tissue Plasminogen
Activator (t-PA)
 1988- A Collaborative Study to Establish the First International Standard for Prourokinase
 1988- A Collaborative Study to Establish the Second International Standard for Streptokinase
 1990- A Collaborative Study to Establish the Second International Standard for Thrombin
 1990- A Collaborative Study to Establish a U.S. Reference for Tissue Plasminogen Activator
 1991- A Collaborative Study to Establish a Standard for Hirudin
 1991- A Collaborative Study to Establish a Potency Assay for Anistreplase
AWARDS RECEIVED

5.  Phi Beta Kappa, Connecticut College.
 American Chemical Society Connecticut Valley Section Award,
Connecticut College, Honors in Chemistry, Magna Cum Laude,
Connecticut College
 Paul Abel Schwartz Prize in Chemistry, Connecticut College.
 Louise M. Dieckman Prize for Excellence in Organ Playing,
Connecticut College.
 FDA Commissioner's Special Citation, Fibrinolytic Review Group,
FDA, 1988.
 National Institutes of Health Award of Merit, 1998
 NHLBI Crystal for Distinguished Service, 2006.
TRAINING
 FDA Laws for Drugs and Biologics
 Fundamentals of NIH Extramural Activities Program
 Successful Middle Management Program
 NIH Health Scientist Administrator (HSA) Associates Program.
 NIH Project Officer Program (Honor Student Commendation)
 NIH Staff Training in Extramural Programs Committee
 NIH Senior Leadership Training, University of Maryland
 Project Management Institute certification-Project Management Professional, 2011.
MAJOR FDA REGULATORY REVIEW COMMITTEES:
1987- Vice-Chairman, Alteplase (Genentech t-PA) Review Committee, IV AMI indication
1987- Streptokinase (Behringwerke AG and Kabi) Review Committee, IV AMI indication
1988- Chairman, Anistreplase (Beecham) Review Committee, IV AMI indication
1989- Chairman, Alteplase (Genentech t-PA) Review Committee PE indication
1990- Coagulation Factor IX (Alpha Therapeutics) Review Committee, Hemophilia B
indication
1991- Chairman, Recombinant Factor VIII (Genetics Institute) Review Committee,
Hemophilia A
REFERENCES AVAILABLE UPON REQUEST (240-393-5614)

6.  Phi Beta Kappa, Connecticut College.
 American Chemical Society Connecticut Valley Section Award,
Connecticut College, Honors in Chemistry, Magna Cum Laude,
Connecticut College
 Paul Abel Schwartz Prize in Chemistry, Connecticut College.
 Louise M. Dieckman Prize for Excellence in Organ Playing,
Connecticut College.
 FDA Commissioner's Special Citation, Fibrinolytic Review Group,
FDA, 1988.
 National Institutes of Health Award of Merit, 1998
 NHLBI Crystal for Distinguished Service, 2006.
TRAINING
 FDA Laws for Drugs and Biologics
 Fundamentals of NIH Extramural Activities Program
 Successful Middle Management Program
 NIH Health Scientist Administrator (HSA) Associates Program.
 NIH Project Officer Program (Honor Student Commendation)
 NIH Staff Training in Extramural Programs Committee
 NIH Senior Leadership Training, University of Maryland
 Project Management Institute certification-Project Management Professional, 2011.
MAJOR FDA REGULATORY REVIEW COMMITTEES:
1987- Vice-Chairman, Alteplase (Genentech t-PA) Review Committee, IV AMI indication
1987- Streptokinase (Behringwerke AG and Kabi) Review Committee, IV AMI indication
1988- Chairman, Anistreplase (Beecham) Review Committee, IV AMI indication
1989- Chairman, Alteplase (Genentech t-PA) Review Committee PE indication
1990- Coagulation Factor IX (Alpha Therapeutics) Review Committee, Hemophilia B
indication
1991- Chairman, Recombinant Factor VIII (Genetics Institute) Review Committee,
Hemophilia A
REFERENCES AVAILABLE UPON REQUEST (240-393-5614)